Digest Réseau Comment ça marche
Réseau
/
Sociétés
AC
Non vérifié

AC Immune SA

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

21 communiqués de presse

Voir tous les communiqués de presse
19/03/2026
Biotechnologie
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
13/03/2026
Biotechnologie
Management/Organisation d'Entreprise
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
05/03/2026
Biotechnologie
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
24/02/2026
Biotechnologie
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
11/12/2025
Biotechnologie
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
11/11/2025
Biotechnologie
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
04/11/2025
Biotechnologie
Management/Organisation d'Entreprise
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
28/10/2025
Biotechnologie
Annonces Économiques
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
24/10/2025
Biotechnologie
Publicité/Marketing/Médias/Communication
Médecine Santé Bien-être
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
25/09/2025
Biotechnologie
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0